Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-... by Coates, LC, Mease, PJ, Gladman, DD, Navarra, S, Bao, W, Gaillez, C

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐co... by Coates, L, Mease, P, Gossec, L, Kirkham, B, Sherif, B, Gaillez, C, Mpofu, S, Jugl, S, Karyekar, C, Gandhi, K

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis by Reich, K, Baraliakos, X, Coates, LC, Elewski, B, Bao, W, Kasparek, T, Gaillez, C, Pournara, E, Aassi, M, Perella, C, Gottlieb, AB

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 stu... by Coates, L, Nash, P, Kvien, TK, Gossec, L, Mease, PJ, Rasouliyan, L, Pricop, L, Jugl, SM, Gandhi, KK, Gaillez, C, Smolen, JS

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies by Coates, L, Wallman, J, McGonagle, D, Schett, G, McInnes, I, Mease, P, Rasouliyan, L, Quebe-Fehling, E, Asquith, D, Fasth, A, Pricop, L, Gaillez, C

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the... by Coates, L, Gladman, D, Nash, P, Fitzgerald, O, Kavanaugh, A, Kvien, T, Gossec, L, Strand, V, Rasouliyan, L, Pricop, L, Ding, K, Jugl, S, Gaillez, C, Future 2 Study Group